Download PDF
Semin Liver Dis 2010; 30(2): 147-159
DOI: 10.1055/s-0030-1253224
© Thieme Medical Publishers

Genetic Determinants of Drug-induced Cholestasis and Intrahepatic Cholestasis of Pregnancy

Christiane Pauli-Magnus1 , Peter J. Meier2 , Bruno Stieger3 , 4
  • 1University Hospital Basel, Basel, Switzerland
  • 2University Basel, Basel, Switzerland
  • 3Division of Clinical Pharmacology and Toxicology, Department of Internal Medicine, University Hospital Zürich, Zürich, Switzerland
  • 4AMC Liver Center, Academic Medical Center, Amsterdam, The Netherlands
Further Information

Publication History

Publication Date:
26 April 2010 (online)

    Permissions and Reprints

ABSTRACT

Intrahepatic cholestasis of pregnancy and drug-induced cholestasis are two clinically important forms of acquired cholestatic liver disease. The understanding of the underlying mechanisms of acquired cholestasis has recently made considerable progress by the identification of canalicular ATP-binding cassette (ABC) transporters as likely targets for these forms of cholestasis. Cholestasis of pregnancy is linked to estrogen and progesterone metabolites. These metabolites have been shown to impair the bile salt export pump (BSEP) function by an indirect mechanism. In addition, genetic variants (as well as mutants) of the genes coding for the phosphatidylcholine translocator MDR3 and BSEP and for the farnesoid X receptor, which is critical in the transcriptional activation of MDR3 (ABCB4) and BSEP (ABCB11) have been associated with intrahepatic cholestasis of pregnancy. The pathogenesis of drug-induced liver injury encompasses a wide spectrum of mechanisms, some of which are still poorly understood. BSEP is now known to be subject to drug inhibition in susceptible patients. Information on genetic factors rendering individuals susceptible to inhibition of BSEP by drugs or their metabolites is still scarce. Besides rare mutations that have been linked to drug-induced cholestasis, the common p.V444A polymorphism of BSEP has been identified as a potential risk factor. In this review, the authors summarize key concepts of physiology of bile formation, diagnostic principles to indentify these forms of acquired cholestasis, as well as pathogenetic mechanisms leading to intrahepatic cholestasis of pregnancy or drug-induced cholestasis. In addition, they review the current knowledge on genetic susceptibility factors for these two forms of cholestasis.

KEYWORDS

Pharmacogenetics - cholestasis - drug-induced - pregnancy

REFERENCES

  • 1 Russell D W. Fifty years of advances in bile acid synthesis and metabolism.  J Lipid Res. 2009;  50(Suppl) S120-S125
    CrossrefPubMedGoogle Scholar
  • 2 Meier P J, Stieger B. Bile salt transporters.  Annu Rev Physiol. 2002;  64 635-661
    CrossrefPubMedGoogle Scholar
  • 3 Trauner M, Boyer J L. Bile salt transporters: molecular characterization, function, and regulation.  Physiol Rev. 2003;  83(2) 633-671
    CrossrefPubMedGoogle Scholar
  • 4 Pauli-Magnus C, Stieger B, Meier Y, Kullak-Ublick G A, Meier P J. Enterohepatic transport of bile salts and genetics of cholestasis.  J Hepatol. 2005;  43(2) 342-357
    CrossrefPubMedGoogle Scholar
  • 5 Hofmann A F, Hagey L R. Bile acids: chemistry, pathochemistry, biology, pathobiology, and therapeutics.  Cell Mol Life Sci. 2008;  65(16) 2461-2483
    CrossrefPubMedGoogle Scholar
  • 6 Hofmann A F. The enterohepatic circulation of bile acids in mammals: form and functions.  Front Biosci. 2009;  14 2584-2598
    PubMedGoogle Scholar
  • 7 Dawson P A, Lan T, Rao A. Bile acid transporters.  J Lipid Res. 2009;  50(12) 2340-2357
    CrossrefPubMedGoogle Scholar
  • 8 Hagenbuch B, Dawson P. The sodium bile salt cotransport family SLC10.  Pflugers Arch. 2004;  447(5) 566-570
    CrossrefPubMedGoogle Scholar
  • 9 Kullak-Ublick G A, Stieger B, Meier P J. Enterohepatic bile salt transporters in normal physiology and liver disease.  Gastroenterology. 2004;  126(1) 322-342
    CrossrefPubMedGoogle Scholar
  • 10 Hagenbuch B, Meier P J. Organic anion transporting polypeptides of the OATP/ SLC21 family: phylogenetic classification as OATP/ SLCO superfamily, new nomenclature and molecular/functional properties.  Pflugers Arch. 2004;  447(5) 653-665
    CrossrefPubMedGoogle Scholar
  • 11 Stieger B, Meier Y, Meier P J. The bile salt export pump.  Pflugers Arch. 2007;  453(5) 611-620
    CrossrefPubMedGoogle Scholar
  • 12 Stieger B. Recent insights into the function and regulation of the bile salt export pump (ABCB11).  Curr Opin Lipidol. 2009;  20(3) 176-181
    CrossrefPubMedGoogle Scholar
  • 13 Reichen J, Paumgartner G. Uptake of bile acids by perfused rat liver.  Am J Physiol. 1976;  231(3) 734-742
    PubMedGoogle Scholar
  • 14 Oude Elferink R P, Paulusma C C. Function and pathophysiological importance of ABCB4 (MDR3 P-glycoprotein).  Pflugers Arch. 2007;  453(5) 601-610
    CrossrefPubMedGoogle Scholar
  • 15 Small D M. Role of ABC transporters in secretion of cholesterol from liver into bile.  Proc Natl Acad Sci U S A. 2003;  100(1) 4-6
    CrossrefPubMedGoogle Scholar
  • 16 Oude Elferink R P, Paulusma C C, Groen A K. Hepatocanalicular transport defects: pathophysiologic mechanisms of rare diseases.  Gastroenterology. 2006;  130(3) 908-925
    CrossrefPubMedGoogle Scholar
  • 17 Hazard S E, Patel S B. Sterolins ABCG5 and ABCG8: regulators of whole body dietary sterols.  Pflugers Arch. 2007;  453(5) 745-752
    CrossrefPubMedGoogle Scholar
  • 18 Alnouti Y. Bile acid sulfation: a pathway of bile acid elimination and detoxification.  Toxicol Sci. 2009;  108(2) 225-246
    CrossrefPubMedGoogle Scholar
  • 19 Zollner G, Trauner M. Molecular mechanisms of cholestasis.  Wien Med Wochenschr. 2006;  156(13-14) 380-385
    CrossrefPubMedGoogle Scholar
  • 20 Nies A T, Keppler D. The apical conjugate efflux pump ABCC2 (MRP2).  Pflugers Arch. 2007;  453(5) 643-659
    CrossrefPubMedGoogle Scholar
  • 21 Geier A, Wagner M, Dietrich C G, Trauner M. Principles of hepatic organic anion transporter regulation during cholestasis, inflammation and liver regeneration.  Biochim Biophys Acta. 2007;  1773(3) 283-308
    CrossrefPubMedGoogle Scholar
  • 22 Ballatori N, Li N, Fang F, Boyer J L, Christian W V, Hammond C L. OST alpha-OST beta: a key membrane transporter of bile acids and conjugated steroids.  Front Biosci. 2009;  14 2829-2844
    PubMedGoogle Scholar
  • 23 Geyer J, Wilke T, Petzinger E. The solute carrier family SLC10: more than a family of bile acid transporters regarding function and phylogenetic relationships.  Naunyn Schmiedebergs Arch Pharmacol. 2006;  372(6) 413-431
    CrossrefPubMedGoogle Scholar
  • 24 Alrefai W A, Gill R K. Bile acid transporters: structure, function, regulation and pathophysiological implications.  Pharm Res. 2007;  24(10) 1803-1823
    CrossrefPubMedGoogle Scholar
  • 25 Weinman S A. Electrogenicity of Na(+)-coupled bile acid transporters.  Yale J Biol Med. 1997;  70(4) 331-340
    PubMedGoogle Scholar
  • 26 Hagenbuch B, Gui C. Xenobiotic transporters of the human organic anion transporting polypeptides (OATP) family.  Xenobiotica. 2008;  38(7-8) 778-801
    CrossrefPubMedGoogle Scholar
  • 27 Kalliokoski A, Niemi M. Impact of OATP transporters on pharmacokinetics.  Br J Pharmacol. 2009;  158(3) 693-705
    CrossrefPubMedGoogle Scholar
  • 28 Kitamura S, Maeda K, Wang Y, Sugiyama Y. Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin.  Drug Metab Dispos. 2008;  36(10) 2014-2023
    CrossrefPubMedGoogle Scholar
  • 29 Link E, Parish S, Armitage J SEARCH Collaborative Group et al. SLCO1B1 variants and statin-induced myopathy—a genomewide study.  N Engl J Med. 2008;  359(8) 789-799
    CrossrefPubMedGoogle Scholar
  • 30 Satlin L M, Amin V, Wolkoff A W. Organic anion transporting polypeptide mediates organic anion/HCO3- exchange.  J Biol Chem. 1997;  272(42) 26340-26345
    CrossrefPubMedGoogle Scholar
  • 31 Li L, Lee T K, Meier P J, Ballatori N. Identification of glutathione as a driving force and leukotriene C4 as a substrate for OATP1, the hepatic sinusoidal organic solute transporter.  J Biol Chem. 1998;  273(26) 16184-16191
    CrossrefPubMedGoogle Scholar
  • 32 Li L, Meier P J, Ballatori N. OATP2 mediates bidirectional organic solute transport: a role for intracellular glutathione.  Mol Pharmacol. 2000;  58(2) 335-340
    PubMedGoogle Scholar
  • 33 Briz O, Romero M R, Martinez-Becerra P et al.. OATP8/1B3-mediated cotransport of bile acids and glutathione: an export pathway for organic anions from hepatocytes?.  J Biol Chem. 2006;  281(41) 30326-30335
    CrossrefPubMedGoogle Scholar
  • 34 Leuthold S, Hagenbuch B, Mohebbi N, Wagner C A, Meier P J, Stieger B. Mechanisms of pH-gradient driven transport mediated by organic anion polypeptide transporters.  Am J Physiol Cell Physiol. 2009;  296(3) C570-C582
    CrossrefPubMedGoogle Scholar
  • 35 Zheng H X, Huang Y, Frassetto L A, Benet L Z. Elucidating rifampin's inducing and inhibiting effects on glyburide pharmacokinetics and blood glucose in healthy volunteers: unmasking the differential effects of enzyme induction and transporter inhibition for a drug and its primary metabolite.  Clin Pharmacol Ther. 2009;  85(1) 78-85
    CrossrefPubMedGoogle Scholar
  • 36 Kellner H M, Christ O, Rupp W, Heptner W. [Resorption, distribution and excretion after administration of 14C-labelled HB 419 in rabbits, rats and dogs].  Arzneimittelforschung. 1969;  19(8, Suppl) 1388-1400
    PubMedGoogle Scholar
  • 37 Stieger B, Fattinger K, Madon J, Kullak-Ublick G A, Meier P J. Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver.  Gastroenterology. 2000;  118(2) 422-430
    CrossrefPubMedGoogle Scholar
  • 38 Hayashi H, Takada T, Suzuki H, Onuki R, Hofmann A F, Sugiyama Y. Transport by vesicles of glycine- and taurine-conjugated bile salts and taurolithocholate 3-sulfate: a comparison of human BSEP with rat Bsep.  Biochim Biophys Acta. 2005;  1738(1-3) 54-62
    PubMedGoogle Scholar
  • 39 Gerloff T, Stieger B, Hagenbuch B et al.. The sister of P-glycoprotein represents the canalicular bile salt export pump of mammalian liver.  J Biol Chem. 1998;  273(16) 10046-10050
    CrossrefPubMedGoogle Scholar
  • 40 Carlton V E, Harris B Z, Puffenberger E G et al.. Complex inheritance of familial hypercholanemia with associated mutations in TJP2 and BAAT.  Nat Genet. 2003;  34(1) 91-96
    CrossrefPubMedGoogle Scholar
  • 41 Stieger B, O'Neill B, Meier P J. ATP-dependent bile-salt transport in canalicular rat liver plasma-membrane vesicles.  Biochem J. 1992;  284(Pt 1) 67-74
    PubMedGoogle Scholar
  • 42 Strautnieks S S, Bull L N, Knisely A S et al.. A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis.  Nat Genet. 1998;  20(3) 233-238
    CrossrefPubMedGoogle Scholar
  • 43 Jansen P LM, Strautnieks S S, Jacquemin E et al.. Hepatocanalicular bile salt export pump deficiency in patients with progressive familial intrahepatic cholestasis.  Gastroenterology. 1999;  117(6) 1370-1379
    CrossrefPubMedGoogle Scholar
  • 44 Byrne J A, Strautnieks S S, Mieli-Vergani G, Higgins C F, Linton K J, Thompson R J. The human bile salt export pump: characterization of substrate specificity and identification of inhibitors.  Gastroenterology. 2002;  123(5) 1649-1658
    CrossrefPubMedGoogle Scholar
  • 45 Noé J, Stieger B, Meier P J. Functional expression of the canalicular bile salt export pump of human liver.  Gastroenterology. 2002;  123(5) 1659-1666
    CrossrefPubMedGoogle Scholar
  • 46 Stieger B. Role of the bile salt export pump, BSEP, in acquired forms of cholestasis.  Drug Metab Rev. 2009;  , December 29 (Epub adhead of print)
    CrossrefPubMedGoogle Scholar
  • 47 Akita H, Suzuki H, Ito K et al.. Characterization of bile acid transport mediated by multidrug resistance associated protein 2 and bile salt export pump.  Biochim Biophys Acta. 2001;  1511(1) 7-16
    CrossrefPubMedGoogle Scholar
  • 48 Vallejo M, Briz O, Serrano M A, Monte M J, Marin J J. Potential role of trans-inhibition of the bile salt export pump by progesterone metabolites in the etiopathogenesis of intrahepatic cholestasis of pregnancy.  J Hepatol. 2006;  44(6) 1150-1157
    CrossrefPubMedGoogle Scholar
  • 49 Huang L, Smit J W, Meijer D K, Vore M. Mrp2 is essential for estradiol-17beta(beta-D-glucuronide)-induced cholestasis in rats.  Hepatology. 2000;  32(1) 66-72
    CrossrefPubMedGoogle Scholar
  • 50 Gonzalez M C, Reyes H, Arrese M et al.. Intrahepatic cholestasis of pregnancy in twin pregnancies.  J Hepatol. 1989;  9(1) 84-90
    CrossrefPubMedGoogle Scholar
  • 51 Reyes H, Sjövall J. Bile acids and progesterone metabolites in intrahepatic cholestasis of pregnancy.  Ann Med. 2000;  32(2) 94-106
    CrossrefPubMedGoogle Scholar
  • 52 Pusl T, Beuers U. Intrahepatic cholestasis of pregnancy.  Orphanet J Rare Dis. 2007;  2 26
    CrossrefPubMedGoogle Scholar
  • 53 Hay J E. Liver disease in pregnancy.  Hepatology. 2008;  47(3) 1067-1076
    CrossrefPubMedGoogle Scholar
  • 54 Geenes V, Williamson C. Intrahepatic cholestasis of pregnancy.  World J Gastroenterol. 2009;  15(17) 2049-2066
    CrossrefPubMedGoogle Scholar
  • 55 Gonzales E, Davit-Spraul A, Baussan C, Buffet C, Maurice M, Jacquemin E. Liver diseases related to MDR3 (ABCB4) gene deficiency.  Front Biosci. 2009;  14 4242-4256
    PubMedGoogle Scholar
  • 56 Kenyon A P, Piercy C N, Girling J, Williamson C, Tribe R M, Shennan A H. Obstetric cholestasis, outcome with active management: a series of 70 cases.  BJOG. 2002;  109(3) 282-288
    CrossrefPubMedGoogle Scholar
  • 57 Jacquemin E, De Vree J M, Cresteil D et al.. The wide spectrum of multidrug resistance 3 deficiency: from neonatal cholestasis to cirrhosis of adulthood.  Gastroenterology. 2001;  120(6) 1448-1458
    CrossrefPubMedGoogle Scholar
  • 58 Bacq Y, Sapey T, Bréchot M C, Pierre F, Fignon A, Dubois F. Intrahepatic cholestasis of pregnancy: a French prospective study.  Hepatology. 1997;  26(2) 358-364
    CrossrefPubMedGoogle Scholar
  • 59 Arrese M, Reyes H. Intrahepatic cholestasis of pregnancy: a past and present riddle.  Ann Hepatol. 2006;  5(3) 202-205
    PubMedGoogle Scholar
  • 60 Lammert F, Marschall H U, Glantz A, Matern S. Intrahepatic cholestasis of pregnancy: molecular pathogenesis, diagnosis and management.  J Hepatol. 2000;  33(6) 1012-1021
    CrossrefPubMedGoogle Scholar
  • 61 Heikkinen J, Mäentausta O, Ylöstalo P, Jänne O. Changes in serum bile acid concentrations during normal pregnancy, in patients with intrahepatic cholestasis of pregnancy and in pregnant women with itching.  Br J Obstet Gynaecol. 1981;  88(3) 240-245
    PubMedGoogle Scholar
  • 62 Lunzer M, Barnes P, Byth K, O'Halloran M. Serum bile acid concentrations during pregnancy and their relationship to obstetric cholestasis.  Gastroenterology. 1986;  91(4) 825-829
    CrossrefPubMedGoogle Scholar
  • 63 Meng L J, Reyes H, Axelson M et al.. Progesterone metabolites and bile acids in serum of patients with intrahepatic cholestasis of pregnancy: effect of ursodeoxycholic acid therapy.  Hepatology. 1997;  26(6) 1573-1579
    CrossrefPubMedGoogle Scholar
  • 64 Meng L J, Reyes H, Palma J, Hernandez I, Ribalta J, Sjövall J. Profiles of bile acids and progesterone metabolites in the urine and serum of women with intrahepatic cholestasis of pregnancy.  J Hepatol. 1997;  27(2) 346-357
    CrossrefPubMedGoogle Scholar
  • 65 Meng L J, Reyes H, Palma J, Hernandez I, Ribalta J, Sjövall J. Effects of ursodeoxycholic acid on conjugated bile acids and progesterone metabolites in serum and urine of patients with intrahepatic cholestasis of pregnancy.  J Hepatol. 1997;  27(6) 1029-1040
    CrossrefPubMedGoogle Scholar
  • 66 Pauli-Magnus C, Lang T, Meier Y et al.. Sequence analysis of bile salt export pump (ABCB11) and multidrug resistance p-glycoprotein 3 (ABCB4, MDR3) in patients with intrahepatic cholestasis of pregnancy.  Pharmacogenetics. 2004;  14(2) 91-102
    CrossrefPubMedGoogle Scholar
  • 67 Jacquemin E. Role of multidrug resistance 3 deficiency in pediatric and adult liver disease: one gene for three diseases.  Semin Liver Dis. 2001;  21(4) 551-562
    Article in Thieme ConnectPubMedGoogle Scholar
  • 68 Kreek M J. Female sex steroids and cholestasis.  Semin Liver Dis. 1987;  7(1) 8-23
    Article in Thieme ConnectPubMedGoogle Scholar
  • 69 Reyes H, Simon F R. Intrahepatic cholestasis of pregnancy: an estrogen-related disease.  Semin Liver Dis. 1993;  13(3) 289-301
    Article in Thieme ConnectPubMedGoogle Scholar
  • 70 Laatikainen T, Karjalainen O. Exertion of progesterone metabolites in urine and bile of pregnant women with intrahepatic cholestasis.  J Steroid Biochem. 1973;  4(6) 641-648
    CrossrefPubMedGoogle Scholar
  • 71 Lindberg M C. Hepatobiliary complications of oral contraceptives.  J Gen Intern Med. 1992;  7(2) 199-209
    CrossrefPubMedGoogle Scholar
  • 72 Meyers M, Slikker W, Pascoe G, Vore M. Characterization of cholestasis induced by estradiol-17 beta-D-glucuronide in the rat.  J Pharmacol Exp Ther. 1980;  214(1) 87-93
    PubMedGoogle Scholar
  • 73 Bossard R, Stieger B, O'Neill B, Fricker G, Meier P J. Ethinylestradiol treatment induces multiple canalicular membrane transport alterations in rat liver.  J Clin Invest. 1993;  91(6) 2714-2720
    CrossrefPubMedGoogle Scholar
  • 74 Madon J, Eckhardt U, Gerloff T, Stieger B, Meier P J. Functional expression of the rat liver canalicular isoform of the multidrug resistance-associated protein.  FEBS Lett. 1997;  406(1-2) 75-78
    CrossrefPubMedGoogle Scholar
  • 75 Simon F R, Fortune J, Iwahashi M, Gartung C, Wolkoff A, Sutherland E. Ethinyl estradiol cholestasis involves alterations in expression of liver sinusoidal transporters.  Am J Physiol. 1996;  271(6 Pt 1) G1043-G1052
    PubMedGoogle Scholar
  • 76 Micheline D, Emmanuel J, Serge E. Effect of ursodeoxycholic acid on the expression of the hepatocellular bile acid transporters (Ntcp and bsep) in rats with estrogen-induced cholestasis.  J Pediatr Gastroenterol Nutr. 2002;  35(2) 185-191
    CrossrefPubMedGoogle Scholar
  • 77 Geier A, Dietrich C G, Gerloff T et al.. Regulation of basolateral organic anion transporters in ethinylestradiol-induced cholestasis in the rat.  Biochim Biophys Acta. 2003;  1609(1) 87-94
    CrossrefPubMedGoogle Scholar
  • 78 Lee J M, Trauner M, Soroka C J, Stieger B, Meier P J, Boyer J L. Expression of the bile salt export pump is maintained after chronic cholestasis in the rat.  Gastroenterology. 2000;  118(1) 163-172
    CrossrefPubMedGoogle Scholar
  • 79 Carreras F I, Lehmann G L, Ferri D, Tioni M F, Calamita G, Marinelli R A. Defective hepatocyte aquaporin-8 expression and reduced canalicular membrane water permeability in estrogen-induced cholestasis.  Am J Physiol Gastrointest Liver Physiol. 2007;  292(3) G905-G912
    CrossrefPubMedGoogle Scholar
  • 80 Kamisako T, Ogawa H. Alteration of the expression of adenosine triphosphate-binding cassette transporters associated with bile acid and cholesterol transport in the rat liver and intestine during cholestasis.  J Gastroenterol Hepatol. 2005;  20(9) 1429-1434
    CrossrefPubMedGoogle Scholar
  • 81 Ruiz M L, Villanueva S S, Luquita M G, Vore M, Mottino A D, Catania V A. Ethynylestradiol increases expression and activity of rat liver MRP3.  Drug Metab Dispos. 2006;  34(6) 1030-1034
    PubMedGoogle Scholar
  • 82 Yamamoto Y, Moore R, Hess H A et al.. Estrogen receptor alpha mediates 17alpha-ethynylestradiol causing hepatotoxicity.  J Biol Chem. 2006;  281(24) 16625-16631
    CrossrefPubMedGoogle Scholar
  • 83 Barth A, Klinger G, Rost M. Influence of ethinyloestradiol propanolsulphonate on serum bile acids in healthy volunteers.  Exp Toxicol Pathol. 2003;  54(5-6) 381-386
    CrossrefPubMedGoogle Scholar
  • 84 Koopen N R, Wolters H, Havinga R et al.. Impaired activity of the bile canalicular organic anion transporter (Mrp2/cmoat) is not the main cause of ethinylestradiol-induced cholestasis in the rat.  Hepatology. 1998;  27(2) 537-545
    CrossrefPubMedGoogle Scholar
  • 85 Mottino A D, Cao J, Veggi L M, Crocenzi F, Roma M G, Vore M. Altered localization and activity of canalicular Mrp2 in estradiol-17beta-D-glucuronide-induced cholestasis.  Hepatology. 2002;  35(6) 1409-1419
    CrossrefPubMedGoogle Scholar
  • 86 Crocenzi F A, Mottino A D, Cao J et al.. Estradiol-17beta-D-glucuronide induces endocytic internalization of Bsep in rats.  Am J Physiol Gastrointest Liver Physiol. 2003;  285(2) G449-G459
    PubMedGoogle Scholar
  • 87 Roma M G, Crocenzi F A, Mottino A D. Dynamic localization of hepatocellular transporters in health and disease.  World J Gastroenterol. 2008;  14(44) 6786-6801
    CrossrefPubMedGoogle Scholar
  • 88 Crocenzi F A, Sánchez Pozzi E J, Ruiz M L et al.. Ca(2+)-dependent protein kinase C isoforms are critical to estradiol 17beta-D-glucuronide-induced cholestasis in the rat.  Hepatology. 2008;  48(6) 1885-1895
    CrossrefPubMedGoogle Scholar
  • 89 Hartgens F, Kuipers H. Effects of androgenic-anabolic steroids in athletes.  Sports Med. 2004;  34(8) 513-554
    CrossrefPubMedGoogle Scholar
  • 90 Maravelias C, Dona A, Stefanidou M, Spiliopoulou C. Adverse effects of anabolic steroids in athletes. A constant threat.  Toxicol Lett. 2005;  158(3) 167-175
    CrossrefPubMedGoogle Scholar
  • 91 Parkinson A B, Evans N A. Anabolic androgenic steroids: a survey of 500 users.  Med Sci Sports Exerc. 2006;  38(4) 644-651
    CrossrefPubMedGoogle Scholar
  • 92 Ishak K G. Hepatic lesions caused by anabolic and contraceptive steroids.  Semin Liver Dis. 1981;  1(2) 116-128
    Article in Thieme ConnectPubMedGoogle Scholar
  • 93 Gurakar A, Caraceni P, Fagiuoli S, Van Thiel D H. Androgenic/anabolic steroid-induced intrahepatic cholestasis: a review with four additional case reports.  J Okla State Med Assoc. 1994;  87(9) 399-404
    PubMedGoogle Scholar
  • 94 Nasr J, Ahmad J. Severe cholestasis and renal failure associated with the use of the designer steroid Superdrol (methasteron): a case report and literature review.  Dig Dis Sci. 2009;  54(5) 1144-1146
    CrossrefPubMedGoogle Scholar
  • 95 Krishnan P V, Feng Z Z, Gordon S C. Prolonged intrahepatic cholestasis and renal failure secondary to anabolic androgenic steroid-enriched dietary supplements.  J Clin Gastroenterol. 2009;  43(7) 672-675
    CrossrefPubMedGoogle Scholar
  • 96 Bellmann R, Feistritzer C, Zoller H et al.. Treatment of intractable pruritus in drug induced cholestasis with albumin dialysis: a report of two cases.  ASAIO J. 2004;  50(4) 387-391
    PubMedGoogle Scholar
  • 97 Phillips M J, Oda M, Funatsu K. Evidence for microfilament involvement in norethandrolone-induced intrahepatic cholestasis.  Am J Pathol. 1978;  93(3) 729-744
    PubMedGoogle Scholar
  • 98 Jacquemin E, Cresteil D, Manouvrier S, Boute O, Hadchouel M. Heterozygous non-sense mutation of the MDR3 gene in familial intrahepatic cholestasis of pregnancy.  Lancet. 1999;  353(9148) 210-211
    CrossrefPubMedGoogle Scholar
  • 99 Wasmuth H E, Glantz A, Keppeler H et al.. Intrahepatic cholestasis of pregnancy: the severe form is associated with common variants of the hepatobiliary phospholipid transporter ABCB4 gene.  Gut. 2007;  56(2) 265-270
    CrossrefPubMedGoogle Scholar
  • 100 Floreani A, Carderi I, Variola A, Rizzotto E R, Nicol J, Bergasa N V. A novel multidrug-resistance protein 2 gene mutation identifies a subgroup of patients with primary biliary cirrhosis and pruritus.  Hepatology. 2006;  43(5) 1152-1154
    CrossrefPubMedGoogle Scholar
  • 101 Schneider G, Paus T C, Kullak-Ublick G A et al.. Linkage between a new splicing site mutation in the MDR3 alias ABCB4 gene and intrahepatic cholestasis of pregnancy.  Hepatology. 2007;  45(1) 150-158
    CrossrefPubMedGoogle Scholar
  • 102 Eloranta M L, Heiskanen J T, Hiltunen M J, Mannermaa A J, Punnonen K R, Heinonen S T. Multidrug resistance 3 gene mutation 1712delT and estrogen receptor alpha gene polymorphisms in Finnish women with obstetric cholestasis.  Eur J Obstet Gynecol Reprod Biol. 2002;  105(2) 132-135
    PubMedGoogle Scholar
  • 103 Dixon P H, Weerasekera N, Linton K J et al.. Heterozygous MDR3 missense mutation associated with intrahepatic cholestasis of pregnancy: evidence for a defect in protein trafficking.  Hum Mol Genet. 2000;  9(8) 1209-1217
    CrossrefPubMedGoogle Scholar
  • 104 Meier Y, Zodan T, Lang C et al.. Increased susceptibility for intrahepatic cholestasis of pregnancy and contraceptive-induced cholestasis in carriers of the 1331T> C polymorphism in the bile salt export pump.  World J Gastroenterol. 2008;  14(1) 38-45
    CrossrefPubMedGoogle Scholar
  • 105 Dixon P H, van Mil S W, Chambers J et al.. Contribution of variant alleles of ABCB11 to susceptibility to intrahepatic cholestasis of pregnancy.  Gut. 2009;  58(4) 537-544
    CrossrefPubMedGoogle Scholar
  • 106 Noe J, Kullak-Ublick G A, Jochum W et al.. Impaired expression and function of the bile salt export pump due to three novel ABCB11 mutations in intrahepatic cholestasis.  J Hepatol. 2005;  43(3) 536-543
    CrossrefPubMedGoogle Scholar
  • 107 Meier Y, Pauli-Magnus C, Zanger U M et al.. Interindividual variability of canalicular ATP-binding-cassette (ABC)-transporter expression in human liver.  Hepatology. 2006;  44(1) 62-74
    CrossrefPubMedGoogle Scholar
  • 108 Byrne J A, Strautnieks S S, Ihrke G et al.. Missense mutations and single nucleotide polymorphisms in ABCB11 impair bile salt export pump processing and function or disrupt pre-messenger RNA splicing.  Hepatology. 2009;  49(2) 553-567
    CrossrefPubMedGoogle Scholar
  • 109 Ho R H, Leake B F, Kilkenny D M et al.. Polymorphic variants in the human bile salt export pump (BSEP; ABCB11): functional characterization and interindividual variability.  Pharmacogenet Genomics. 2010;  20(1) 45-57
    CrossrefPubMedGoogle Scholar
  • 110 Van Mil S W, Milona A, Dixon P H et al.. Functional variants of the central bile acid sensor FXR identified in intrahepatic cholestasis of pregnancy.  Gastroenterology. 2007;  133(2) 507-516
    CrossrefPubMedGoogle Scholar
  • 111 Ananthanarayanan M, Balasubramanian N, Makishima M, Mangelsdorf D J, Suchy F J. Human bile salt export pump promoter is transactivated by the farnesoid X receptor/bile acid receptor.  J Biol Chem. 2001;  276(31) 28857-28865
    CrossrefPubMedGoogle Scholar
  • 112 Huang L, Zhao A, Lew J L et al.. Farnesoid X receptor activates transcription of the phospholipid pump MDR3.  J Biol Chem. 2003;  278(51) 51085-51090
    CrossrefPubMedGoogle Scholar
  • 113 Keitel V, Vogt C, Häussinger D, Kubitz R. Combined mutations of canalicular transporter proteins cause severe intrahepatic cholestasis of pregnancy.  Gastroenterology. 2006;  131(2) 624-629
    CrossrefPubMedGoogle Scholar
  • 114 Zimmer V, Müllenbach R, Simon E, Bartz C, Matern S, Lammert F. Combined functional variants of hepatobiliary transporters and FXR aggravate intrahepatic cholestasis of pregnancy.  Liver Int. 2009;  29(8) 1286-1288
    CrossrefPubMedGoogle Scholar
  • 115 Lang C, Meier Y, Stieger B et al.. Mutations and polymorphisms in the bile salt export pump and the multidrug resistance protein 3 associated with drug-induced liver injury.  Pharmacogenet Genomics. 2007;  17(1) 47-60
    CrossrefPubMedGoogle Scholar
  • 116 Lee W M. Drug-induced hepatotoxicity.  N Engl J Med. 2003;  349(5) 474-485
    CrossrefPubMedGoogle Scholar
  • 117 Meier Y, Cavallaro M, Roos M et al.. Incidence of drug-induced liver injury in medical inpatients.  Eur J Clin Pharmacol. 2005;  61(2) 135-143
    CrossrefPubMedGoogle Scholar
  • 118 Shapiro M A, Lewis J H. Causality assessment of drug-induced hepatotoxicity: promises and pitfalls.  Clin Liver Dis. 2007;  11(3) 477-505, v , v
    CrossrefPubMedGoogle Scholar
  • 119 Bleibel W, Kim S, D'Silva K, Lemmer E R. Drug-induced liver injury: review article.  Dig Dis Sci. 2007;  52(10) 2463-2471
    CrossrefPubMedGoogle Scholar
  • 120 Schuster D, Laggner C, Langer T. Why drugs fail—a study on side effects in new chemical entities.  Curr Pharm Des. 2005;  11(27) 3545-3559
    CrossrefPubMedGoogle Scholar
  • 121 Smith D A, Schmid E F. Drug withdrawals and the lessons within.  Curr Opin Drug Discov Devel. 2006;  9(1) 38-46
    PubMedGoogle Scholar
  • 122 Abboud G, Kaplowitz N. Drug-induced liver injury.  Drug Saf. 2007;  30(4) 277-294
    CrossrefPubMedGoogle Scholar
  • 123 Ramachandran R, Kakar S. Histological patterns in drug-induced liver disease.  J Clin Pathol. 2009;  62(6) 481-492
    CrossrefPubMedGoogle Scholar
  • 124 Chitturi S, George J. Hepatotoxicity of commonly used drugs: nonsteroidal anti-inflammatory drugs, antihypertensives, antidiabetic agents, anticonvulsants, lipid-lowering agents, psychotropic drugs.  Semin Liver Dis. 2002;  22(2) 169-183
    Article in Thieme ConnectPubMedGoogle Scholar
  • 125 Bell L N, Chalasani N. Epidemiology of idiosyncratic drug-induced liver injury.  Semin Liver Dis. 2009;  29(4) 337-347
    Article in Thieme ConnectPubMedGoogle Scholar
  • 126 Liss G, Lewis J H. Drug-induced liver injury: what was new in 2008?.  Expert Opin Drug Metab Toxicol. 2009;  5(8) 843-860
    CrossrefPubMedGoogle Scholar
  • 127 Bénichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting.  J Hepatol. 1990;  11(2) 272-276
    CrossrefPubMedGoogle Scholar
  • 128 Pizzagalli F, Varga Z, Huber R D, Folkers G, Meier P J, St-Pierre M V. Identification of steroid sulfate transport processes in the human mammary gland.  J Clin Endocrinol Metab. 2003;  88(8) 3902-3912
    Google Scholar
  • 129 Grube M, Köck K, Karner S et al.. Modification of OATP2B1-mediated transport by steroid hormones.  Mol Pharmacol. 2006;  70(5) 1735-1741
    Google Scholar
  • 130 Gui C, Miao Y, Thompson L et al.. Effect of pregnane X receptor ligands on transport mediated by human OATP1B1 and OATP1B3.  Eur J Pharmacol. 2008;  584(1) 57-65
    CrossrefPubMedGoogle Scholar
  • 131 Sugiyama D, Kusuhara H, Shitara Y, Abe T, Sugiyama Y. Effect of 17 beta-estradiol-D-17 beta-glucuronide on the rat organic anion transporting polypeptide 2-mediated transport differs depending on substrates.  Drug Metab Dispos. 2002;  30(2) 220-223
    CrossrefPubMedGoogle Scholar
  • 132 Arias I M. Cyclosporin, the biology of the bile canaliculus, and cholestasis.  Gastroenterology. 1993;  104(5) 1558-1560
    PubMedGoogle Scholar
  • 133 Böhme M, Müller M, Leier I, Jedlitschky G, Keppler D. Cholestasis caused by inhibition of the adenosine triphosphate-dependent bile salt transport in rat liver.  Gastroenterology. 1994;  107(1) 255-265
    PubMedGoogle Scholar
  • 134 Krähenbühl S, Talos C, Fischer S, Reichen J. Toxicity of bile acids on the electron transport chain of isolated rat liver mitochondria.  Hepatology. 1994;  19(2) 471-479
    PubMedGoogle Scholar
  • 135 Treiber A, Schneiter R, Häusler S, Stieger B. Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil.  Drug Metab Dispos. 2007;  35(8) 1400-1407
    CrossrefPubMedGoogle Scholar
  • 136 Fattinger K, Funk C, Pantze M et al.. The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions.  Clin Pharmacol Ther. 2001;  69(4) 223-231
    CrossrefPubMedGoogle Scholar
  • 137 Fouassier L, Kinnman N, Lefèvre G et al.. Contribution of mrp2 in alterations of canalicular bile formation by the endothelin antagonist bosentan.  J Hepatol. 2002;  37(2) 184-191
    CrossrefPubMedGoogle Scholar
  • 138 Mano Y, Usui T, Kamimura H. Effects of bosentan, an endothelin receptor antagonist, on bile salt export pump and multidrug resistance-associated protein 2.  Biopharm Drug Dispos. 2007;  28(1) 13-18
    CrossrefPubMedGoogle Scholar
  • 139 Borst P, Zelcer N, van de Wetering K, Poolman B. On the putative co-transport of drugs by multidrug resistance proteins.  FEBS Lett. 2006;  580(4) 1085-1093
    CrossrefPubMedGoogle Scholar
  • 140 Meier P J. Canalicular bile formation: beyond single transporter functions.  J Hepatol. 2002;  37(2) 272-273
    CrossrefPubMedGoogle Scholar
  • 141 Takada T, Weiss H M, Kretz O, Gross G, Sugiyama Y. Hepatic transport of PKI166, an epidermal growth factor receptor kinase inhibitor of the pyrrolo-pyrimidine class, and its main metabolite, ACU154.  Drug Metab Dispos. 2004;  32(11) 1272-1278
    CrossrefPubMedGoogle Scholar
  • 142 Masubuchi Y. Metabolic and non-metabolic factors determining troglitazone hepatotoxicity: a review.  Drug Metab Pharmacokinet. 2006;  21(5) 347-356
    CrossrefPubMedGoogle Scholar
  • 143 Julie N L, Julie I M, Kende A I, Wilson G L. Mitochondrial dysfunction and delayed hepatotoxicity: another lesson from troglitazone.  Diabetologia. 2008;  51(11) 2108-2116
    CrossrefPubMedGoogle Scholar
  • 144 Preininger K, Stingl H, Englisch R et al.. Acute troglitazone action in isolated perfused rat liver.  Br J Pharmacol. 1999;  126(1) 372-378
    CrossrefPubMedGoogle Scholar
  • 145 Funk C, Ponelle C, Scheuermann G, Pantze M. Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity: in vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat.  Mol Pharmacol. 2001;  59(3) 627-635
    PubMedGoogle Scholar
  • 146 Marion T L, Leslie E M, Brouwer K L. Use of sandwich-cultured hepatocytes to evaluate impaired bile acid transport as a mechanism of drug-induced hepatotoxicity.  Mol Pharm. 2007;  4(6) 911-918
    CrossrefPubMedGoogle Scholar
  • 147 Snow K L, Moseley R H. Effect of thiazolidinediones on bile acid transport in rat liver.  Life Sci. 2007;  80(8) 732-740
    CrossrefPubMedGoogle Scholar
  • 148 Daly A K, Donaldson P T, Bhatnagar P DILIGEN Study et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin.  Nat Genet. 2009;  41(7) 816-819
    CrossrefPubMedGoogle Scholar
  • 149 Daly A K, Day C P. Genetic association studies in drug-induced liver injury.  Semin Liver Dis. 2009;  29(4) 400-411
    Article in Thieme ConnectPubMedGoogle Scholar
  • 150 Pauli-Magnus C, Meier P J. Hepatobiliary transporters and drug-induced cholestasis.  Hepatology. 2006;  44(4) 778-787
    CrossrefPubMedGoogle Scholar
  • 151 Tirona R G, Leake B F, Merino G, Kim R B. Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans.  J Biol Chem. 2001;  276(38) 35669-35675
    CrossrefPubMedGoogle Scholar
  • 152 Nishizato Y, Ieiri I, Suzuki H et al.. Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics.  Clin Pharmacol Ther. 2003;  73(6) 554-565
    CrossrefPubMedGoogle Scholar
  • 153 Mwinyi J, Johne A, Bauer S, Roots I, Gerloff T. Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics.  Clin Pharmacol Ther. 2004;  75(5) 415-421
    CrossrefPubMedGoogle Scholar
  • 154 Niemi M, Schaeffeler E, Lang T et al.. High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1).  Pharmacogenetics. 2004;  14(7) 429-440
    CrossrefPubMedGoogle Scholar
  • 155 Nozawa T, Minami H, Sugiura S, Tsuji A, Tamai I. Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms.  Drug Metab Dispos. 2005;  33(3) 434-439
    CrossrefPubMedGoogle Scholar
  • 156 Ho R H, Tirona R G, Leake B F et al.. Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics.  Gastroenterology. 2006;  130(6) 1793-1806
    Google Scholar

Peter J Meier-AbtM.D. 

University Basel, Petersplatz 35

4003 Basel, Switzerland

Email: peter.meier-abt@unibas.ch